Abbreviations AE Adverse event BMI Body mass index CFR Code of Federal Regulations CI Confidence interval CSF Cerebrospinal fluid EHR Electronic health record GI Gastrointestinal GIP Glucosedependent insulinotropic polypeptide GLP-1 Glucagonlike peptide-1 GLP-1 RA GLP-1 receptor agonist GRADE Grading of Recommendations, Assessment, Development and Evaluations ICD-10 International Classification of Diseases, 10th Revision ICP Intracranial pressure IIH Idiopathic intracranial hypertension IQR Interquartile range NKCC1 NaKCl cotransporter 1 OCT Optical coherence tomography ONSF Optic nerve sheath fenestration OR Odds ratio PMD Perimetric mean deviation PRISMA Preferred Reporting Items for Systematic Reviews and MetaAnalyses RA Receptor agonist RCT Randomized controlled trial RNFL Retinal nerve fiber layer ROBINS-I Risk Of Bias In Nonrandomized Studies of Interventions RR Risk ratio SAE Serious adverse event SD Standard deviation Authors contributions J.O.: Conceptualization, Formal analysis, Visualization, Data curation, Validation, Writing: Original Draft, Writing: Review & Editing
This means that it activates all 3 of the hormonal pathways that have been linked to weight loss, including [1]: Each of these hormones has a role to play in your body, such as suppressing appetite, slowing digestion, increasing fat metabolism and regulating blood sugars
Saxenda can also be a stepping stone for patients who intend to transition to weekly agents after gaining early momentum or confirming that GLP-1 therapy is a good fit for them
Understanding that mechanism is the first step toward managing it
